Jmac Enterprises LLC Buys 1,566 Shares of Merck & Co., Inc. (NYSE:MRK)

Jmac Enterprises LLC grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 8.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,867 shares of the company’s stock after acquiring an additional 1,566 shares during the period. Jmac Enterprises LLC’s holdings in Merck & Co., Inc. were worth $2,256,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Industrial Alliance Investment Management Inc. raised its stake in shares of Merck & Co., Inc. by 2.6% in the first quarter. Industrial Alliance Investment Management Inc. now owns 3,193 shares of the company’s stock valued at $421,000 after buying an additional 80 shares during the period. IRON Financial LLC lifted its holdings in Merck & Co., Inc. by 4.6% during the second quarter. IRON Financial LLC now owns 1,811 shares of the company’s stock valued at $224,000 after purchasing an additional 80 shares during the last quarter. Argent Capital Management LLC boosted its position in Merck & Co., Inc. by 0.8% during the second quarter. Argent Capital Management LLC now owns 10,521 shares of the company’s stock worth $1,302,000 after purchasing an additional 81 shares during the period. Forza Wealth Management LLC increased its stake in shares of Merck & Co., Inc. by 0.8% in the second quarter. Forza Wealth Management LLC now owns 10,480 shares of the company’s stock worth $1,297,000 after purchasing an additional 82 shares in the last quarter. Finally, Vista Investment Partners LLC lifted its stake in shares of Merck & Co., Inc. by 2.0% during the 2nd quarter. Vista Investment Partners LLC now owns 4,164 shares of the company’s stock valued at $516,000 after buying an additional 82 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on MRK shares. UBS Group cut their price target on Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. Truist Financial lowered their target price on shares of Merck & Co., Inc. from $132.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday. Morgan Stanley decreased their price target on shares of Merck & Co., Inc. from $130.00 to $123.00 and set an “equal weight” rating on the stock in a report on Friday, November 1st. Evercore ISI upgraded Merck & Co., Inc. to a “strong-buy” rating in a research report on Tuesday, July 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price target on shares of Merck & Co., Inc. in a research report on Thursday, October 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.80.

Merck & Co., Inc. Trading Up 0.3 %

NYSE MRK opened at $101.02 on Thursday. The stock’s 50 day moving average is $111.37 and its 200 day moving average is $120.33. The company has a quick ratio of 1.22, a current ratio of 1.47 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $255.86 billion, a PE ratio of 21.24, a P/E/G ratio of 1.46 and a beta of 0.40. Merck & Co., Inc. has a twelve month low of $98.60 and a twelve month high of $134.63.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Merck & Co., Inc. had a net margin of 19.23% and a return on equity of 37.32%. The firm had revenue of $16.66 billion for the quarter, compared to the consensus estimate of $16.47 billion. During the same period in the prior year, the firm earned $2.13 EPS. The company’s revenue was up 4.4% compared to the same quarter last year. Research analysts forecast that Merck & Co., Inc. will post 7.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.